DCGI - Drugs Controller General of India, IBAT - Ileal bile acid transporter, IBS-C - Irritable bowel syndrome with constipation

References:
1. Gray JR. What is chronic constipation? Definition and diagnosis. Can J Gastroenterol. 2011;25 Suppl B(Suppl B):7B–10B.
2. Masaoka T. Current management of chronic constipation in Japan. Keio J Med. 2023;72(4):95–101.
3. Ghoshal UC. Chronic constipation in Rome IV era: The Indian perspective. Indian J Gastroenterol. 2017;36(3):163–173.
4. Bagepally RS. Management of chronic constipation in comorbid conditions. Int J Res Med Sci. 2022;10(6):1382–1389.
5. Mosińska P, Fichna J, Storr M. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
World J Gastroenterol. 2015;21(24):7436–7442.
6. Shono T, Hyakutake H. Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation: A retrospective study. Renal Replacement Therapy. 2020;6:21.
7. Eswaran S, Guentner A, Chey WD. Emerging pharmacologic therapies for constipation-predominant irritable bowel syndrome and chronic constipation. J Neurogastroenterol Motil. 2014;20(2):141–15.

For the use of a Registered Medical Practitioner, Hospital or a Laboratory only.
GGI-CO-A1-AQS-300041570-ELC-H24-0460 DOI : 01/09/2024 & DOE : 30/08/2026